Azura Ophthalmics
Yair Alster, MD, co-founder of Azura Ophthalmics serves as the company’s Chief Technology Officer. Yair did his residency in Ophthalmology at the Tel-Aviv Medical Center. His entrepreneurial career started at Notal Vision, now a commercial stage company developing home diagnostics for age-related macular degeneration (ADM). In 2008 Yair joined Forsight Labs in California, where he served as CTO of Nexis Vision, a contact lens developer for post-surgical treatment and astigmatism. He was also CMO and co-founder of Forsight Vision 4 (acquired by Roche-Genentech) and Forsight Vision 5 (acquired by Allergan). In 2013 Yair returned to Israel where he co-founded Forsight Vision6, makers of intraocular lens (IOL), Pres-By Vision, an accommodating contact lens developer and Azura Ophthalmics.
This person is not in any offices
Azura Ophthalmics
1 followers
Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the United States. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking.